



Temocillin is not substrate for OprD2 porin from *Pseudomonas aeruginosa*

H. Chalhoub¹, M. Winterhalter², D. Pletzer², Y. Braun², H. Weingart², P.M. Tulkens¹ and F. Van Bambeke¹

¹ Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium; ² Biophysics, School of Engineering and Science, Jacobs University Bremen, Germany.

Françoise Van Bambeke
av. Mounier 73, B1.73.05
1200 Brussels - Belgium
francoise.vanbambeke@uclouvain.be

Introduction & Aims

Resistance to beta-lactams in *P. aeruginosa* (*Pa*) can be mediated by a decreased bacterial outer membrane permeability (e.g., loss or modification of the OprD2 porin or overexpression of efflux pumps), associated or not with overproduction of AmpC cephalosporinases, extended-spectrum beta-lactamases (ESBLs) or carbapenemases. Temocillin (TMO; 6- α -methoxy-ticarcellin), a beta-lactam stable against most beta-lactamases (including most ESBLs, AmpC and KPC-type carbapenemases), is proposed as a sparing drug for carbapenems. Temocillin, however, is usually reported as devoid of useful activity against *P. aeruginosa*, which we showed to be due to active efflux by the constitutively-expressed MexAB-OprM pump [1]. Yet, we showed that a subset of strains (~ 20 %) collected from cystic fibrosis (CF) patients harbored natural mutations in *mexA* or *mexB* genes, which restored their susceptibility to temocillin, suggesting a potential therapeutic interest in this specific population [2].

Our aim was to determine whether temocillin is substrate for the OprD2 porin, for which mutations or loss of expression are known to confer high resistance to carbapenems in *P. aeruginosa*.

Methods







MICs were determined by microdilution in Muller Hinton broth, according to CLSI guidelines [3], using as test organisms (a) PA14 and its OprD2 defective mutant (PA14 Δ OprD2) and (b) a porin-deficient *E. coli* (K-12 W3110: Δ ompF Δ ompC) transformed with either a pB22 empty vector or a pB22-OprD2 construct coding for the *P. aeruginosa* OprD2 under the control of the PBAD promoter of the arabinose operon.

Acknowledgments

H.C. is Boursier of the Belgian Fonds de la recherche dans l'industrie et l'agriculture (FRIA). This work was supported by the Région Wallonne and the Belgian Fonds de la Recherche scientifique.

Results


Table 1 : MICs (mg/L) for carbapenems and carboxypenicillins in PA14 WT versus its OprD2 defective mutant

						
<i>Pa</i> strains	Meropenem	Imipenem	Doripenem	Carbencillin	Ticarcillin	Temocillin
PA14 (wt)	0.5	0.25	0.25	64	32	256
PA14 Δ OprD2	8	2	2	64	32	256

→ MICs of carbapenems were higher in the OprD2 defective mutant of PA14 while the MICs of temocillin, as that of other carboxypenicillins, remained unchanged.

Table 2 : MICs (mg/L) for carbapenems and carboxypenicillins in porin-deficient *E. coli* over-expressing OprD2

	Antibiotic MIC (mg/L)	
	1. Empty vector	+++OprD2
Meropenem	1	0.125
Imipenem	0.25	0.032
Doripenem	0.5	0.064
Carbencillin	>2048	>2048
Ticarcillin	>2048	>2048
Temocillin	32	32



→ MICs of carbapenems were lower in *E. coli* over-expressing OprD2 than in the strain transformed by the empty vector.

→ On the contrary, MICs of carboxypenicillins, including temocillin, were the same, whether oprD2 was expressed or not.

Conclusions

Temocillin, as other carboxypenicillins, is not a substrate for OprD2.

Testing susceptibility to temocillin in carbapenem-resistant strains isolated from CF patients (including those with mutations or loss of expression of OprD2 porin) could be useful.

Reference

- Buyck *et al.*, J Antimicrob Chemother. 2012 Mar;67(3):771-5.
- Chalhoub *et al.*, "Comparative in vitro activity of temocillin and other β -lactams against *Pseudomonas aeruginosa* isolated from cystic fibrosis patients" (poster P02, ESCMID Conference on Reviving Old Antibiotics, Vienna, Austria, 22-24 October, 2014), <http://www.facm.ucl.ac.be/posters/2014/ESCMID-old-antibiotics-2014/Chalhoub-et-al-temocillin-cystic-fibrosis-Vienna-2014.pdf>
- Performance Standards for Antimicrobial Susceptibility Testing; 24th Informational Supplement. CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.

A copy of this poster will be made available after the meeting at <http://www.facm.ucl.ac.be/posters.htm>